Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

Vilon

KE, L-Lys-L-Glu, lysylglutamic acid

Quick Stats
Studies 40
Trials 100
Recruiting NA INTERVENTIONAL NCT06230614

Effect of Diluent Volume on Colistin Inhalation Therapy

View on ClinicalTrials.gov Updated Dec 15, 2025

Brief Summary

The aim of this study is to investigate the impact of different diluent volumes for the same dosage of colistin in mechanically ventilated respiratory patients receiving colistin inhalation therapy. The study aims to determine whether the diluent volume has an effect on clinical outcomes, including ICU length of stay, total hospitalization duration, duration of respiratory support within 28 days, mortality rates within 28 days and 90 days, as well as analyze the pharmacokinetic profile of colistin in blood and bronchoalveolar lavage fluid. Additionally, the study will evaluate the incidence of nebulizer malfunctions and blockages. The findings of this research will help identify the optimal diluent volume for colistin inhalation therapy in clinical practice.

Detailed Description

Background: Colistin is an antibiotic used to treat infections caused by multidrug-resistant Gram-negative bacteria. In recent years, it has been widely utilized as an inhaled antibiotic for the treatment of respiratory infections in critically ill patients on mechanical ventilation. Despite the increasing use of colistin inhalation therapy for ventilator-associated pneumonia, the clinical impact of diluent volume on nebulization efficiency remains unclear. Study Design: A single-center, prospective, randomized controlled trial. Methods: The study plans to enroll 60 participants. Colistin inhalation therapy will be administered using a blocked stratified random allocation. The control group will receive colistin 6 MU diluted in 6 ml of normal saline (1 MU per 1 ml), while the experimental group will receive colistin 6 MU diluted in 12 ml of normal saline (1 MU per 2 ml). The dosage, frequency, and administration method of colistin inhalation will follow the clinical standard of 6 MU, administered every 8 hours, continuously for 7 days. Effect: The investigators anticipate that the clinical outcomes and pharmacokinetics of colistin inhalation therapy will not differ significantly between different diluent volumes. Based on comprehensive evaluation, a diluent volume of 12 ml is considered more suitable than 6 ml for the dilution of colistin.

Interventions

Name: Colistin 1 MU in normal saline 1 ml
Type: OTHER
Description: Colistin 1 MU diluted in normal saline 1 ml, total volume of 12 ml
Name: Colistin 1 MU in normal saline 2 ml
Type: OTHER
Description: Colistin 1 MU diluted in normal saline 2 ml, total volume of 12 ml

Primary Outcomes

Measure: Drug concentration
TimeFrame: One hour post inhalation therapy with colistin on the third day of treatment
Description: Drug concentration in bronchoalveolar lavage fluid and blood

Trial Information

NCT ID

NCT06230614

Status

Recruiting

Study Type

INTERVENTIONAL

Phases

NA

Sponsor

Fu Jen Catholic University

Last Updated

December 15, 2025